Alembic Pharmaceuticals informs about press release

Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 533573 | NSE: APLLTD

01 Apr 2024 Evaluate

Alembic Pharmaceuticals has informed that the Company has received one US Food & Drug Administration (USFDA) Product Approval (Tentative) during the quarter ended 31st March, 2024. The summary statement giving brief of the product approval received during the quarter ended 31st March, 2024 is enclosed. Alembic has a cumulative total of 197 ANDA approvals (170 final approvals and 27 tentative approvals) from USFDA. Press release of same is enclosed.

The above information is a part of company’s filings submitted to BSE.

Peers

Company Name	CMP
Sun Pharma. Inds.	1835.50
Dr. Reddys Labs.	1171.10
Cipla	1371.45
Lupin	2144.70
Zydus Lifesciences	1153.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.